Vizora日本語

ONO PharmaceuticalONO PHARMACEUTICAL CO., LTD.4528東証プライム医薬品FY ending Mar 2024, consolidated, IFRS

ONO Pharmaceutical FY ending Mar 2022 results

ONO Pharmaceutical brought in ¥361.4B in revenue.

Revenue changed +25.2% from the prior year.

What changed from last year

FY ending Mar 2019 → FY ending Mar 2022

Revenue
+25.2%¥288.6B → ¥361.4B
Net income attributable to owners
+56.2%¥51.5B → ¥80.5B
Operating cash flow
-7.4%¥66.8B → ¥61.8B

Where the money goes

FY ending Mar 2019 → FY ending Mar 2022

※ Cost of revenue is not disclosed; expenses are combined

※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains

Where ¥100 of sales goes

A machine-readable operating income value exists, but it is not in the validated published data, so the chart is omitted.

Sources

Show source documents (4)

  • EDINET (FSA Japan)

    訂正有価証券報告書－第78期(2025/04/01－2026/03/31)

    ID S100YOIE2026-07-08Open

  • EDINET (FSA Japan)

    有価証券報告書－第75期(2022/04/01－2023/03/31)

    ID S100QU2A2023-06-23Open

  • EDINET (FSA Japan)

    有価証券報告書－第74期(令和3年4月1日－令和4年3月31日)

    ID S100OBYA2022-06-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第73期(令和2年4月1日－令和3年3月31日)

    ID S100LIVI2021-06-18Open

Extracted from XBRL: 9 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image